Targeted cancer therapy can sound like something designed by engineers in a secret laboratory. In reality, the idea is fairly straightforward: identify a specific feature helping cancer cells grow, then use a medication aimed at that feature. Alunbrig is one of these precision treatments.
Alunbrig, whose active ingredient is brigatinib, is an oral tyrosine kinase inhibitor used in adults with metastatic non-small cell lung cancer that tests positive for an anaplastic lymphoma kinase, or ALK, rearrangement. Because it targets ALK-driven cancer rather than attacking every rapidly dividing cell, its benefits, side effects, and monitoring requirements differ from those of traditional chemotherapy.
What Is Alunbrig?
Alunbrig is a prescription kinase inhibitor approved by the U.S. Food and Drug Administration for adults with ALK-positive metastatic non-small cell lung cancer, commonly abbreviated as ALK-positive metastatic NSCLC. An FDA-approved test must confirm that the tumor carries the relevant ALK alteration before treatment begins.
ALK rearrangements create an abnormal protein that can send nonstop signals telling cancer cells to multiply. Brigatinib blocks ALK-related signaling pathways, which may slow tumor growth or shrink tumors. Think of the abnormal ALK protein as a smoke alarm stuck in permanent panic mode. Alunbrig does not remove the alarm, but it may interrupt the electrical signal that keeps the commotion going.
Is Alunbrig chemotherapy?
No. Alunbrig is a targeted therapy, not conventional chemotherapy. Both approaches can treat cancer, but they work differently. Chemotherapy generally affects rapidly dividing cells throughout the body. Brigatinib is designed to interfere with selected molecular targets, particularly abnormal ALK signaling. Targeted does not mean side-effect-free, however. It simply means the drug has a more specific biological target.
How effective is Alunbrig?
In the ALTA-1L clinical trial, previously untreated patients with advanced ALK-positive NSCLC received either Alunbrig or crizotinib. Independent reviewers reported a median progression-free survival of 24 months with Alunbrig and 11 months with crizotinib. The confirmed overall response rate was 74% with Alunbrig and 62% with crizotinib. Among a small subgroup with measurable brain metastases, the confirmed intracranial response rate was 78% with Alunbrig and 26% with crizotinib. Trial results describe groups of patients and cannot predict exactly how one individual will respond.
Alunbrig Dosage and Administration
The standard Alunbrig dosage uses a seven-day lead-in period rather than beginning at the full maintenance dose immediately:
- Days 1 through 7: 90 milligrams by mouth once daily.
- Day 8 and afterward: If the initial dose is tolerated, increase to 180 milligrams once daily.
Treatment generally continues until the cancer progresses or side effects become unacceptable. Alunbrig is available as 30-mg, 90-mg, and 180-mg tablets. The seven-day starting period is important because serious lung reactions can occur early in treatment, particularly during the first week.
How should Alunbrig be taken?
- Take it at approximately the same time every day.
- Take it with or without food.
- Swallow the tablet whole.
- Do not crush, chew, or split the tablet.
- If vomiting occurs after a dose, do not take a replacement tablet.
- If a dose is missed, skip it and take the next dose at the regular time.
Taking a second tablet after vomiting or doubling the next dose may increase drug exposure without restoring the original dose in a predictable way. This is one situation where enthusiasm is not rewarded.
What happens after a long treatment interruption?
If Alunbrig has been interrupted for 14 days or longer for a reason other than an adverse reaction, the prescribing information recommends restarting at 90 mg once daily for seven days before returning to the previously tolerated dosage. Patients should contact their oncology team before restarting because the appropriate plan may depend on why treatment stopped.
Alunbrig dose reductions
An oncologist may pause treatment or reduce the dose when significant side effects develop. The labeled reduction schedule is summarized below:
| Current daily dose | First reduction | Second reduction | Third reduction |
|---|---|---|---|
| 180 mg | 120 mg | 90 mg | 60 mg |
| 90 mg | 60 mg | Discontinue permanently if 60 mg is not tolerated | Not applicable |
After a dose has been reduced because of an adverse reaction, the FDA labeling advises against increasing it again. Severe kidney or liver impairment can also require a lower dose. These adjustments should be calculated and supervised by the prescribing clinician.
Common Alunbrig Side Effects
Side effects vary from person to person. Some patients experience several symptoms, while others mainly develop laboratory abnormalities that are discovered during routine monitoring. In the ALTA-1L trial, commonly reported reactions included diarrhea, rash, cough, high blood pressure, fatigue, nausea, muscle pain, shortness of breath, abdominal discomfort, headache, vomiting, itching, constipation, swelling, and back pain.
| Adverse reaction | Percentage reported with Alunbrig in ALTA-1L |
|---|---|
| Diarrhea | 53% |
| Rash | 40% |
| Cough | 35% |
| Hypertension | 32% |
| Fatigue | 32% |
| Nausea | 30% |
| Muscle pain | 28% |
| Shortness of breath | 25% |
| Headache | 22% |
These percentages include reactions of different severity levels and do not prove that Alunbrig caused every event. Clinical trial populations also differ from patients seen in routine practice. A symptom diary can help the care team identify patterns, such as diarrhea after certain meals, fatigue at a particular time of day, or muscle discomfort that becomes progressively worse.
Laboratory abnormalities
Alunbrig can change laboratory values even when the patient feels reasonably well. In ALTA-1L, frequently observed abnormalities included increased creatine phosphokinase, AST, ALT, lipase, amylase, and blood glucose. Changes in phosphorus, magnesium, hemoglobin, and lymphocyte counts were also reported. That is why laboratory appointments are part of treatment rather than decorative events placed on the calendar to keep everyone busy.
Serious Alunbrig Side Effects and Warning Signs
Interstitial lung disease and pneumonitis
Alunbrig can cause severe, life-threatening, or fatal lung inflammation known as interstitial lung disease or pneumonitis. In ALTA-1L, ILD or pneumonitis occurred in 5.1% of patients, with some cases appearing during the first eight days. New or worsening shortness of breath, cough, chest discomfort, fever, or difficulty breathing requires prompt medical evaluation. These symptoms can also come from infection, a blood clot, or cancer progression, so attempting a home diagnosis is not a safe strategy.
High blood pressure and slow heart rate
Hypertension occurred in 32% of Alunbrig-treated patients in ALTA-1L, and Grade 3 hypertension occurred in 13%. Blood pressure should be controlled before treatment, checked after approximately two weeks, and monitored at least monthly afterward. Brigatinib can also cause bradycardia, or an unusually slow heart rate. Dizziness, faintness, unusual weakness, chest pain, or a noticeably slow pulse should be reported.
Vision changes
Blurred vision, double vision, flashes of light, light sensitivity, reduced visual sharpness, and floaters have been reported. New or worsening visual symptoms may require treatment interruption and an eye examination. Sudden or severe vision changes should not be saved for the next routine appointment.
Muscle injury and elevated CPK
Creatine phosphokinase, or CPK, is an enzyme that may rise when muscle tissue is irritated or damaged. CPK elevation occurred in 81% of patients in ALTA-1L, although most laboratory elevations were not severe. Unexplained muscle pain, tenderness, cramps, or weakness should be reported, particularly when the symptoms are worsening or interfering with normal activities.
Pancreatic, liver, and blood sugar problems
Alunbrig can increase pancreatic enzymes, including lipase and amylase. It may also raise liver enzymes or blood glucose. Upper abdominal pain that extends toward the back, persistent vomiting, yellow skin or eyes, dark urine, extreme thirst, frequent urination, or unusual weakness warrants medical attention. Patients with diabetes may need closer glucose monitoring or changes to diabetes medication.
Photosensitivity
Brigatinib can make skin more sensitive to sunlight. Patients are advised to limit sun exposure during treatment and for at least five days after the last dose. Protective clothing, a hat, broad-spectrum UVA and UVB sunscreen, and lip balm with an SPF of at least 30 are recommended outdoors. Apparently, even targeted therapy occasionally assigns homework involving a large hat.
Alunbrig Interactions and Precautions
Brigatinib is affected by medications that influence the CYP3A enzyme system. Strong or moderate CYP3A inhibitors can increase brigatinib exposure and potentially increase adverse reactions. Strong or moderate CYP3A inducers can lower exposure and may reduce effectiveness. Depending on the interacting medication, the oncology team may avoid the combination, adjust the Alunbrig dose, or recommend an alternative treatment.
Examples of medicines or substances that may be relevant include certain antifungal drugs, macrolide antibiotics, seizure medicines, HIV medications, rifampin, diltiazem, verapamil, St. John’s wort, and grapefruit products. This is not a complete interaction list. Patients should provide the oncology pharmacist with an updated list of prescriptions, over-the-counter medicines, vitamins, and supplements before treatment and whenever something new is added.
Pregnancy, contraception, and breastfeeding
Alunbrig may harm a developing fetus. Females who can become pregnant should use effective nonhormonal contraception during treatment and for at least four months after the final dose. Males with partners who can become pregnant should use effective contraception during treatment and for at least three months after the last dose. Hormonal contraceptives may be less effective because of drug interactions. Breastfeeding is not recommended during treatment or for one week after the final dose.
Alternatives to Alunbrig
Several ALK inhibitors are available for ALK-positive lung cancer. Possible alternatives include alectinib, lorlatinib, ensartinib, crizotinib, and ceritinib. These medications are not simple brand-name substitutes for one another. They differ in dosing, ability to reach tumors in the brain, activity against resistance mutations, interactions, and side-effect profiles.
Alectinib
Alectinib, sold as Alecensa, is a later-generation ALK inhibitor frequently used for advanced ALK-positive NSCLC. It can also be used after surgery in certain patients with earlier-stage ALK-positive disease. Its adverse effects may include constipation, fatigue, muscle problems, liver enzyme changes, swelling, slow heart rate, and kidney-related complications. It may be considered when its treatment history, safety profile, and expected brain activity fit the patient’s needs.
Lorlatinib
Lorlatinib, sold as Lorbrena, is a third-generation ALK inhibitor with substantial activity in the central nervous system and against several ALK resistance mutations. It may be used as an initial therapy or after another ALK inhibitor stops working. However, it can cause high cholesterol or triglycerides, swelling, peripheral neuropathy, weight gain, and cognitive, mood, speech, or behavioral effects. The possibility of strong disease control must therefore be weighed against a notably different safety profile.
Ensartinib
Ensartinib, sold in the United States as Ensacove, is another later-generation ALK inhibitor for advanced ALK-positive NSCLC. Rash and liver enzyme abnormalities are among the considerations associated with treatment. As a newer U.S. option, access, insurance coverage, prior therapy, brain involvement, and individual medical history may influence whether it is selected.
Crizotinib and ceritinib
Crizotinib was the first ALK inhibitor approved for advanced ALK-positive NSCLC. It remains useful in selected situations, although later-generation medications generally provide stronger control in the brain. Ceritinib is another ALK inhibitor, but gastrointestinal and liver-related adverse effects can complicate treatment. Current treatment planning commonly favors a later-generation ALK inhibitor when appropriate.
Chemotherapy and clinical trials
If ALK-targeted medicines stop working or cannot be tolerated, options may include platinum-based chemotherapy, pemetrexed-containing regimens, localized treatment for limited areas of progression, or enrollment in a clinical trial. A repeat tissue biopsy or liquid biopsy may reveal a resistance mechanism that helps guide the next treatment. The sequence matters: the best alternative depends not only on what is available, but also on which ALK inhibitor the cancer has already encountered.
Monitoring During Alunbrig Treatment
Patients taking Alunbrig commonly undergo regular examinations, imaging, blood pressure checks, and laboratory testing. Monitoring may include:
- Blood pressure and heart rate
- Fasting blood glucose
- Liver function tests and bilirubin
- CPK levels
- Amylase and lipase
- Kidney function and electrolytes
- Assessment of breathing and lung symptoms
- Eye evaluation when vision changes occur
- CT or MRI scans to evaluate the cancer, including brain imaging when appropriate
The schedule is individualized. A patient with diabetes may need additional glucose checks, while someone taking medication that slows the heart rate may need closer cardiovascular monitoring. Keeping laboratory and imaging appointments is essential because important changes may develop before obvious symptoms appear.
Practical Treatment Experience: What the First Month May Look Like
Although no two treatment experiences are identical, the first month of Alunbrig often has a recognizable rhythm. It usually begins with testing rather than tablets. The oncology team confirms ALK positivity, reviews medications and supplements, checks blood pressure, and orders baseline laboratory tests. Patients may also have brain imaging because ALK-positive lung cancer can involve the central nervous system and treatment decisions may depend on that information.
The first seven days can feel unusually important because the starting dose is 90 mg rather than the eventual 180-mg maintenance dose. Many patients organize the tablet around an established habit, such as breakfast or brushing their teeth. A pill organizer may help, provided the tablets remain intact and are protected appropriately. Setting a daily alarm can also prevent the familiar evening mystery of, “Did I take it, or did I merely think very seriously about taking it?”
During this opening week, breathing deserves special attention. A mild cough may already be present because of lung cancer, which can make symptom tracking complicated. Recording the baseline level of coughing, breathlessness, temperature, and activity tolerance before the first dose gives the care team something useful for comparison. A noticeably worse cough, new shortness of breath, chest pain, fever, or rapidly reduced exercise tolerance should be reported promptly rather than monitored casually at home. Early pulmonary reactions are one reason the step-up dosage and first-week vigilance matter.
After the dose increases to 180 mg, some people notice gastrointestinal symptoms, fatigue, rash, headache, or muscle discomfort. Practical responses may include eating smaller meals, maintaining hydration, using skin products approved by the care team, and planning demanding activities for the part of the day when energy is highest. Patients should ask before taking an over-the-counter antidiarrheal, pain reliever, herbal remedy, or supplement. “Natural” products can still interact with cancer medication; poison ivy is natural too, and nobody invites it to lunch.
Home blood pressure readings can be valuable, especially for patients with a history of hypertension. Measurements should be taken while seated and rested, using a properly fitted cuff. Recording the values is more useful than trying to remember them during an appointment. Patients with diabetes may follow a similar routine for glucose because brigatinib can worsen blood sugar control.
Laboratory results sometimes become the main story even when daily life feels normal. CPK, liver enzymes, lipase, amylase, or glucose may rise without dramatic symptoms. A treatment pause or dose reduction in this situation does not automatically mean Alunbrig has failed. Dose modification is a standard safety tool designed to keep treatment tolerable. In the ALTA-1L trial, 38% of patients required a dose reduction because of adverse reactions, while 13% permanently discontinued treatment for an adverse reaction.
Emotionally, the first scan after starting treatment can be difficult. Patients may feel hopeful and terrified in alternating five-minute shifts. It helps to write down questions before the visit: Has the tumor changed? Are brain lesions controlled? Are current symptoms caused by treatment or disease? Is the present dose still appropriate? What findings would trigger a switch to another ALK inhibitor?
The most useful habit is open communication. Patients do not receive bonus points for enduring severe symptoms silently. Early reporting may allow the care team to pause treatment, reduce the dose, treat the symptom, or rule out an urgent complication. The goal is not merely to take Alunbrig every day. The goal is to use it as safely and effectively as possible while preserving function and quality of life.
Frequently Asked Questions About Alunbrig
Can Alunbrig cure ALK-positive lung cancer?
Alunbrig is generally used to control metastatic ALK-positive NSCLC rather than cure it. It may shrink tumors and delay progression for a substantial period, but resistance can eventually develop. Ongoing scans and molecular testing help determine whether treatment remains effective.
How long do patients take Alunbrig?
The labeled recommendation is to continue until disease progression or unacceptable toxicity. Some patients remain on therapy for months or years, while others switch sooner because of resistance or side effects.
Can Alunbrig be taken with food?
Yes. It may be taken with or without food. Consistency can make the routine easier, but a special meal is not required for absorption. Grapefruit and grapefruit juice should generally be avoided because they may increase brigatinib exposure.
Does Alunbrig cause hair loss?
Hair loss is not among the most prominent common reactions in the FDA trial tables. Individual experiences can still vary, and other cancer treatments, medical conditions, or nutritional issues may contribute to hair changes.
What should a patient do before switching to an alternative?
The oncology team may review prior ALK inhibitors, side effects, brain metastases, imaging results, and molecular resistance findings. Patients should not substitute one ALK inhibitor for another or use leftover tablets because each medication has its own dose, interactions, and monitoring requirements.
Conclusion
Alunbrig is an important targeted treatment for adults with ALK-positive metastatic non-small cell lung cancer. Its standard schedule begins with 90 mg once daily for seven days and then increases to 180 mg once daily when tolerated. The medication has demonstrated meaningful control of advanced disease, including activity against brain metastases, but it also requires careful monitoring.
Common Alunbrig side effects include diarrhea, rash, cough, fatigue, nausea, muscle pain, and hypertension. More serious risks include lung inflammation, liver injury, slow heart rate, visual problems, increased pancreatic enzymes, muscle injury, high blood sugar, and fetal harm. Alternatives such as alectinib, lorlatinib, ensartinib, crizotinib, ceritinib, chemotherapy, or a clinical trial may be considered according to prior treatment, resistance findings, brain involvement, and individual health factors.
Successful treatment depends on more than swallowing a daily tablet. Reporting symptoms early, completing laboratory tests, reviewing drug interactions, and discussing dose adjustments can make Alunbrig therapy safer and more manageable.
